메뉴 건너뛰기




Volumn 47, Issue 6, 2012, Pages 461-465

Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type i (scheie syndrome): A 6.5-year detailed follow-up

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IMMUNOGLOBULIN G ANTIBODY; LARONIDASE; LEVO IDURONIDASE;

EID: 84868591907     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2012.08.010     Document Type: Article
Times cited : (17)

References (16)
  • 2
    • 59449083175 scopus 로고    scopus 로고
    • Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis i
    • L.A. Clarke, J.E. Wraith, and M. Beck Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I Pediatrics 123 2009 229 240
    • (2009) Pediatrics , vol.123 , pp. 229-240
    • Clarke, L.A.1    Wraith, J.E.2    Beck, M.3
  • 3
    • 57649092465 scopus 로고    scopus 로고
    • A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis i
    • R. Giugliani, V.M. Rojas, and A.M. Martins A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I Mol Genet Metab 96 2009 13 19
    • (2009) Mol Genet Metab , vol.96 , pp. 13-19
    • Giugliani, R.1    Rojas, V.M.2    Martins, A.M.3
  • 4
    • 0035905889 scopus 로고    scopus 로고
    • Enzyme-replacement therapy in mucopolysaccharidosis i
    • E.D. Kakkis, J. Muenzer, and G.E. Tiller Enzyme-replacement therapy in mucopolysaccharidosis I N Engl J Med 344 2001 182 188
    • (2001) N Engl J Med , vol.344 , pp. 182-188
    • Kakkis, E.D.1    Muenzer, J.2    Tiller, G.E.3
  • 5
    • 34447121276 scopus 로고    scopus 로고
    • Enzyme replacement therapy in patients who have mucopolysaccharidosis i and are younger than 5 years: Results of a multinational study of recombinant human alpha-l-iduronidase (laronidase)
    • J.E. Wraith, M. Beck, and R. Lane Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: Results of a multinational study of recombinant human alpha-l-iduronidase (laronidase) Pediatrics 120 2007 e37 e46
    • (2007) Pediatrics , vol.120
    • Wraith, J.E.1    Beck, M.2    Lane, R.3
  • 6
    • 2342666229 scopus 로고    scopus 로고
    • Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase)
    • J.E. Wraith, L.A. Clarke, and M. Beck Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase) J Pediatr 144 2004 581 588
    • (2004) J Pediatr , vol.144 , pp. 581-588
    • Wraith, J.E.1    Clarke, L.A.2    Beck, M.3
  • 7
    • 34547906935 scopus 로고    scopus 로고
    • Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome
    • J.A. Thomas, S. Jacobs, J. Kierstein, and J. Van Hove Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome J Inherit Metab Dis 29 2006 762
    • (2006) J Inherit Metab Dis , vol.29 , pp. 762
    • Thomas, J.A.1    Jacobs, S.2    Kierstein, J.3    Van Hove, J.4
  • 8
    • 33846407580 scopus 로고    scopus 로고
    • Restricted upper extremity range of motion in mucopolysaccharidosis type I: No response to one year of enzyme replacement therapy
    • J. Cox-Brinkman, M.J. Smeulders, C.E. Hollak, and F.A. Wijburg Restricted upper extremity range of motion in mucopolysaccharidosis type I: No response to one year of enzyme replacement therapy J Inherit Metab Dis 30 2007 47 50
    • (2007) J Inherit Metab Dis , vol.30 , pp. 47-50
    • Cox-Brinkman, J.1    Smeulders, M.J.2    Hollak, C.E.3    Wijburg, F.A.4
  • 9
    • 77953232381 scopus 로고    scopus 로고
    • Efficacy of recombinant human alpha-l-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type i patients
    • A. Tylki-Szymanska, J. Marucha, A. Jurecka, M. Syczewska, and B. Czartoryska Efficacy of recombinant human alpha-l-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients J Inherit Metab Dis 33 2010 151 157
    • (2010) J Inherit Metab Dis , vol.33 , pp. 151-157
    • Tylki-Szymanska, A.1    Marucha, J.2    Jurecka, A.3    Syczewska, M.4    Czartoryska, B.5
  • 10
    • 33846198829 scopus 로고    scopus 로고
    • A follow-up study of MPS i patients treated with laronidase enzyme replacement therapy for 6 years
    • M. Sifuentes, R. Doroshow, and R. Hoft A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years Mol Genet Metab 90 2007 171 180
    • (2007) Mol Genet Metab , vol.90 , pp. 171-180
    • Sifuentes, M.1    Doroshow, R.2    Hoft, R.3
  • 11
    • 77956502514 scopus 로고    scopus 로고
    • Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS i patients
    • G.V. Coppa, D. Buzzega, and L. Zampini Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients Glycobiology 20 2010 1259 1273
    • (2010) Glycobiology , vol.20 , pp. 1259-1273
    • Coppa, G.V.1    Buzzega, D.2    Zampini, L.3
  • 12
    • 84881016898 scopus 로고    scopus 로고
    • Scheie syndrome: Enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression
    • (Epub ahead of print)
    • S. Illsinger, T. Lucke, and H. Hartmann Scheie syndrome: Enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression J Inherit Metab Dis 2009 Nov 4 (Epub ahead of print)
    • (2009) J Inherit Metab Dis
    • Illsinger, S.1    Lucke, T.2    Hartmann, H.3
  • 13
    • 59449100963 scopus 로고    scopus 로고
    • Mucopolysaccharidosis I: Management and treatment guidelines
    • J. Muenzer, J.E. Wraith, and L.A. Clarke Mucopolysaccharidosis I: Management and treatment guidelines Pediatrics 123 2009 19 29
    • (2009) Pediatrics , vol.123 , pp. 19-29
    • Muenzer, J.1    Wraith, J.E.2    Clarke, L.A.3
  • 14
    • 71649093573 scopus 로고    scopus 로고
    • Anthropometric data of 14 patients with mucopolysaccharidosis I: Retrospective analysis and efficacy of recombinant human alpha-l-iduronidase (laronidase)
    • A. Tylki-Szymanska, A. Rozdzynska, A. Jurecka, J. Marucha, and B. Czartoryska Anthropometric data of 14 patients with mucopolysaccharidosis I: Retrospective analysis and efficacy of recombinant human alpha-l-iduronidase (laronidase) Mol Genet Metab 99 2010 10 17
    • (2010) Mol Genet Metab , vol.99 , pp. 10-17
    • Tylki-Szymanska, A.1    Rozdzynska, A.2    Jurecka, A.3    Marucha, J.4    Czartoryska, B.5
  • 15
    • 79959785835 scopus 로고    scopus 로고
    • Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: The relevance of clinical trial end points
    • E. Glamuzina, E. Fettes, and K. Bainbridge Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: The relevance of clinical trial end points J Inherit Metab Dis 34 2011 749 754
    • (2011) J Inherit Metab Dis , vol.34 , pp. 749-754
    • Glamuzina, E.1    Fettes, E.2    Bainbridge, K.3
  • 16
    • 74049159044 scopus 로고    scopus 로고
    • Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up
    • O. Gabrielli, L.A. Clarke, S. Bruni, and G.V. Coppa Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up Pediatrics 125 2010 e183 e187
    • (2010) Pediatrics , vol.125
    • Gabrielli, O.1    Clarke, L.A.2    Bruni, S.3    Coppa, G.V.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.